Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80. The stock has a market capitalization of $43.65 million, a price-to-earnings ratio of -0.54 and a beta of 2.52.

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

CHF 27 million investment significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with ...

Nvidia and Broadcom are among the new 4-star stocks as the market plunged. How we use your information depends on the product and service that you use and your relationship with us. We may use it ...

NBE Therapeutics, founded in 2012 and acquired by Boehringer Ingelheim in 2020, headquartered in Basel, Switzerland, is a renowned biotechnology company at the forefront of developing next-generation ...

Domestic pharmaceutical players heaved a sigh of relief in trade on April 3, while the other sectors see intense selling pressure, as the White House has excluded pharmaceuticals products from the ...

A digital therapeutic (DTx) is defined as “health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...